Carbon monoxide lowers IOP

Article

CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with a intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology.

CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology.

Professor F Drago of the University of Catania Medical School, Catania, Italy and colleagues injected [alpha]-chymotrypsin into rabbit eyes to induce ocular hypertension, and then assessed the effects of administering CORM-3 at doses of 0.001, 0.01, 0.1 and 1%. In a separate trial arm, the team induced ocular hypertension through subconjunctival betamethasone injections and administered CORM-3. In each trial arm, control subjects were treated with inactive CORM-3 (iCORM-3).

In both trial arms, administration of CORM-3 was associated with a reduction in IOP; dosage amount was positively correlated with the amount of IOP reduction. The control subjects experienced no IOP reduction.

The researchers therefore concluded that CORM-3 is associated with a reduction of IOP in two separate animal models of induced ocular hypertension. This correlation between carbon monoxide modulation and IOP has been established by previous studies.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.